Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glutamine for Myocardial Protection in Elective On-Pump CABG with Low EF
NCT04560309Phase 3Completed
- Sponsor
- National Cardiovascular Center Harapan Kita
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alanyl glutamine in Myocardial injury, sponsored by National Cardiovascular Center Harapan Kita. Started Jan 2021; status: completed.
02
Drugs
alanyl glutamine
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT04560309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560309.